Potential Complications of Lung Cancer Screening: “License to Smoke”

Potential Complications of Lung Cancer Screening: “License to Smoke”

Multiple prospective and retrospective research studies have looked at the question of whether people who smoke decide not to quit smoking, because CT screening will prevent them from dying from lung cancer.  There is general agreement that there is no evidence that quit rates are lower in individuals participating in CT screening.

There is no evidence that screened individuals who have quit resume smoking after beginning screening.

There is some evidence that CT screening represents a window of opportunity to initiate smoking cessation efforts.

It is generally agreed, that centers of excellence in lung cancer screening will 

ASK and record the smoking history of CT screening participants and evaluate willingness to try to quit

ADVISE them to quit

ASSIST them by offering participation in a smoking cessation program in conjunction with screening

AUDIT smoking cessation status at the next screening appointment

If a person undergoing screening is able to quit smoking, he or she will derive a further benefit i.e. that further damage to lungs, heart and blood vessels will stop immediately and that risk of progressive disease in these body organs as well as risk of cancer in the mouth and throat, lungs, esophagus and bladder will diminish progressively over time, compared with those who continue to smoke.

Potential complications of lung cancer screening: Inconvenience

Published by Frederic Grannis

I am a retired thoracic surgeon, formerly Clinical Professor of Thoracic Surgery at City of Hope National Medical Center in Duarte, CA, who spent more than 40 years treating lung cancer and other diseases caused by smoking tobacco industry products. I served on the Lung Cancer Guideline Committee of the National Comprehansive Cancer Network (NCCN) for ten years, on the Scietific Advisory Board of the U. Of California’s Tobacco Related Disease Research Projects for three years and as an investigator with the International Early Lung Cancer Action Program (IELCAP) for twenty years.

Leave a comment

Your email address will not be published. Required fields are marked *